口服固體製劑 (OSDF)：心血管市場

FDA 批准的高血壓藥物 API

示例視圖

OSDF 用於高血壓適應症的藥物佔心血管領域所有已批准 API 的 90% 以上。 該組包括主要處方藥，例如：

示例屏幕

本報告考察了心血管適應症口服固體製劑 (OSDF) 市場，包括按供應商、主要產品和藥物類別分類的詳細數據。

內容

• 心血管口服固體劑型 (OSDF)
• 執行摘要
• 一般 SDF：產品注意事項
• 常見的固體劑型：心血管適應症
• 高血壓
• 心血管治療類別：除高血壓外的所有類別
• 高血壓適應症 OSDF 藥物的主要供應商
• 藥品類別：供應商的市場佔有率
• 藥物類別：ACE 抑製劑（Abbvie、Graviti Pharms 等）
• 藥物類別：Ace 抑製劑（Graviti Pharms、Zydus Pharma USA 等）
• 藥物類別：腎上腺素受體阻滯劑（Able、Mylan 等）
• 藥物類別：腎上腺素受體阻滯劑（Mylan、Zydus Pharms 等）
• 藥物類別：血管緊張素 II 受體（Ajanta Pharma Ltd、Zydus Pharms 等）
• 藥物類別：鈣通道阻滯劑（Accord Healthcare、Mutual Pharm 等）
• 藥物類別：鈣通道阻滯劑（Mylan、Zydus Pharms 等）
• 藥物類別：利尿劑（Actavis、Monarch Pharms 等）
• 藥物類別：利尿劑（Actavis、Monarch Pharms 等）
• 藥物類別：血管擴張劑 (Actavis/Woodward)
• 心血管適應症的 OSDF 供應商
  • Accord Healthcare
  • Actavis
  • Alembic
  • Amneal Pharms
  • ANI Pharms
  • Apotex
  • Aurobindo
  • Dr. Reddy's
  • Glenmark
  • Hikma
  • Lupin
  • Mylan
  • Sandoz
  • Sun Pharma
  • Teva
  • Torrent Pharms
  • Watson Labs
  • Zydus Pharms USA
  • OSDF-劑量圖

Introduction

Greystone Research is pleased to announce the publication of a new life science information resource, a comprehensive overview of the markets, products and participants providing the driving force behind the OSDF segment of the drug delivery sector. The report has been designed and developed to provide pharmaceutical company decision makers, drug developers and formulators, drug device designers, and industry strategists with a detailed understanding of the expanding impact of Ora; Solid Dosage Forms on therapies, pharmaceutical strategies and healthcare treatment protocols. Provider organization business managers, healthcare administrators and investors will also benefit from this publication.

Generating Product Improvements in a Mature Market

The generic solid dosage form drug segment is a rapidly evolving and highly unpredictable environment that has been a challenge to decision makers attempting to map strategies for success in this segment. There are 600 distinct APIs for which there is at least one approved generic solid dosage form ANDA. These APIs account for over four thousand approved ANDAs. Including all approved doses, the current universe of generic solid dosage forms consists of thousands of unique tablet and capsule products. These products are marketed and supplied by more than 800 companies. Competition among the various drug and therapeutic classes is uneven, with the top ten segments accounting for a disproportionate level of activity and revenue. Understanding the underlying factors affecting business performance is key to attaining financial targets.

FDA Approved Hypertension APIs

SAMPLE VIEW

OSDF drugs indicated for Hypertension represent more than 90 % of all approved APIs in the Cardiology market segment. This group includes a number of well-known prescription medicines, including:

Other non-hypertensive drugs approved for Cardiology indications include APIs indicated for Angina, Dyslipidemia, Heart Rhythm, Myocardial Infarction, and Peripheral Blood flow.

Drug Strength and Dosing

The visualization on the below illustrates the formulation challenges for OSDF service and technology suppliers. The wide range of dosing categories and the resulting process and QA issues they represent presents opportunities as well facility and equipment issues.

SAMPLE VIEW

Table of Contents

• Oral Solid Dosage Forms for Cardiology
• Executive Summary
• Generic SDFs - Product Considerations
• Generic Solid Dosage Forms - Cardiology Indications
• Hypertension
• Cardiology Therapeutic Classes: All Classes excluding Hypertension
• Leading Suppliers of OSDF Drugs Indicated for Hypertension
• Drug Class - Market Presence by Supplier
• Drug Class - ACE Inhibitors (Abbvie o Graviti Pharms)
• Drug Class - Ace Inhibitors (Graviti Pharms to Zydus Pharma USA)
• Drug Class - Adrenoceptor Blocking Agent (Able to Mylan)
• Drug Class - Adrenoceptor Blocking Agent (Mylan to Zydus Pharms)
• Drug Class - Angiotensin II Receptor (Ajanta Pharma Ltd to Zydus Pharms)
• Drug Class - Calcium Channel Blocker (Accord Healthcare to Mutual Pharm)
• Drug Class - Calcium Channel Blocker (Mylan to Zydus Pharms)
• Drug Class - Diuretic (Actavis to Monarch Pharms)
• Drug Class - Diuretic (Actavis to Monarch Pharms)
• Drug Class - Vasodilator (Actavis to Woodward)

• Suppliers of OSDFs Indicated for Cardiology
  • Accord Healthcare
  • Actavis
  • Alembic
  • Amneal Pharms
  • ANI Pharms
  • Apotex
  • Aurobindo
  • Dr. Reddy's
  • Glenmark
  • Hikma
  • Lupin
  • Mylan
  • Mylan (Continued)
  • Sandoz
  • Sun Pharma
  • Teva
  • Torrent Pharms
  • Watson Labs
  • Zydus Pharms USA
  • OSDF - Dosage Maps